Explore. Learn. Join the conversation.

Working Group on New TB Drugs

Stop TB Partnership

Launch of the Good Participatory Practice Guidelines for TB Drug Trials

cptr gpp tb

The Stakeholder and Community Engagement Workgroup of the Critical Path to TB Drug Regimens initiative launches guidelines that will facilitate the involvement of communities and participants in the conduct of TB drug trials.

5 Jul 2012
by Working Group

Posted in Announcements, TB Drug Development, TB News

TB R&D Weekly Update: Janssen Seeks Approval from FDA for Bedaquiline

janssen2

This week it was announced the Janssen Pharmaceuticals, Inc., a pharmaceutical company of Johnson & Johnson, filed a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) for their drug Bedaquiline (a.k.a. TMC-207).

7 Jun 2012
by Working Group

Posted in Announcements, TB Drug Development, TB News

TB R&D Weekly Update: Delamanid Shows Promise against Multidrug-Resistant TB

Delamanid (OPC-67683)

This week, efficacy data from the recently completed Phase 2 randomized placebo-controlled trial in MDR patients evaluating delamanid with background treatment compared to placebo with background treatment was published yesterday in the New England Journal of Medicine. Delamanid (OPC-67683) is a new agent derived from the nitro-dihydro-imidazooxazole class of compounds that inhibits mycolic acid synthesis. The abstract and overview of news coverage are presented, as well as, additional links to TB R&D news.

25 May 2012

TB R&D Weekly Update: Expanding Our Options for TB Treatment

tb-e1332174457196

For this week’s update, we will highlight three recent articles that look at repurposing and optimizing drugs already on the market or looking at novel targets and drug classes for TB. Additional links to TB R&D news are included.

26 Jan 2012
by Working Group

Posted in TB Drug Development, TB News

TB R&D Weekly Update: SQ109 and PNU Compounds Additive

JAC cover

In this week’s article, we look at two drugs in our Global TB Drug Pipeline and how they interact with each other: SQ109 (class: Ethylenediamines, Sequella) and PNU-100480 (called Sutezolid, class: Oxazolidinone, Pfizer). Additional links to TB R&D news are included.

29 Sep 2011
by Working Group

Posted in Events, TB Drug Development, TB News

TB R&D Weekly Update: ICAAC and TB Drug Clinical Workshop

ICAAC

On September 16, the 4th International Workshop on Clinical Pharmacology of Tuberculosis Drugs was held adjacent to the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) which was held from September 17 to 19. Between the two meetings, there were many updates related to TB drug development. Additional links to TB R&D are included.

8 Sep 2011

TB R&D Weekly Update: TB Drug Updates in Future Medicinal Chemistry

fmccover

Last week we posted information about two special issues of Future Medicinal Chemistry focused on neglected diseases. Future Medicinal Chemistry (September 2011, Volume 3, Number 11) have a few articles on tuberculosis drug development. Additional links to TB R&D news are included.

12 Jul 2011
by Working Group

Posted in TB Drug Development, TB News

TB R&D Weekly Update: Early bactericidal activity of OPC-67683

compound-OPC67683

This week, we review a recent article published in the July issue of IJTLD on the TB drug candidate OPC-67683 whose new generic name is delamanid. Diacon, et al., present data showing that delamanid is safe, well-tolerated with significant early bactericidal activity. Links to additional TB R&D news is included.

25 May 2011
by Working Group

Posted in Announcements, TB News

Announcement: Promising TB vaccine candidate progresses to Phase I clinical trials

tbvi

The MTBVAC01 vaccine candidate, developed to protect people against tuberculosis, will start Phase I clinical trials early in 2012. This was announced by the Spanish biopharmaceutical company Biofabri. The candidate was developed by the University of Zaragoza, Spain and is part of the international portfolio of TuBerculosis Vaccine Initiative (TBVI). Tuberculosis causes almost two million deaths per year.

TB R&D Weekly Update: Marine Drug Discovery Symposium at the NYAS

NYAS

This week in TB R&D, we are highlighting a symposium hosted by The New York Academy of Sciences entitled “New Frontiers in Marine Drug Discovery” on May 20, 2011. This 1-day symposium will overview the current state of the art in Marine Biomedicine and its role in the context of the drug discovery process. Additional TB R&D news links are included.